1. Home
  2. PXED vs JANX Comparison

PXED vs JANX Comparison

Compare PXED & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PXED

Phoenix Education Partners Inc.

N/A

Current Price

$29.00

Market Cap

1.0B

Sector

Real Estate

ML Signal

N/A

Logo Janux Therapeutics Inc.

JANX

Janux Therapeutics Inc.

HOLD

Current Price

$14.04

Market Cap

847.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PXED
JANX
Founded
1976
2017
Country
United States
United States
Employees
3400
108
Industry
Other Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
847.1M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
PXED
JANX
Price
$29.00
$14.04
Analyst Decision
Buy
Buy
Analyst Count
7
13
Target Price
$44.29
$47.00
AVG Volume (30 Days)
79.5K
870.0K
Earning Date
04-07-2026
05-08-2026
Dividend Yield
3.07%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$10,000,000.00
Revenue This Year
$3.85
N/A
Revenue Next Year
$4.49
N/A
P/E Ratio
$11.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$23.52
$12.12
52 Week High
$38.19
$35.34

Technical Indicators

Market Signals
Indicator
PXED
JANX
Relative Strength Index (RSI) 48.92 43.52
Support Level $28.60 $13.88
Resistance Level $30.85 $14.44
Average True Range (ATR) 1.40 0.55
MACD 0.02 -0.08
Stochastic Oscillator 46.88 37.35

Price Performance

Historical Comparison
PXED
JANX

About PXED Phoenix Education Partners Inc.

Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.

About JANX Janux Therapeutics Inc.

Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.

Share on Social Networks: